MS vs TGTX · P/E 20, rev $41.93B vs P/E 18, rev $240.3M
Morgan Stanley (MS) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Edward N. Pick.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported MS revenue for 2026-06-30 was $41.93B. Net income was $11.15B. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
MS currently screens at market cap $344.27B and trailing P/E 19.8. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the MS and TGTX stock pages for the full models.
Not investment advice.